Nirogy Therapeutics: Funding, Investors & Team (Oct 2026)
Nirogy Therapeutics is a biotechnology company developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.
Nirogy Therapeutics has raised $16.5M across 1 funding round on record, the most recent a Series A of $16.5M announced in Jan 2021.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nirogy Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2021.
Nirogy Therapeutics Funding Rounds
Nirogy Therapeutics Founders and Leadership Team
Contact details for the Nirogy Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Nirogy Therapeutics Funding Compared to Other Biotechnology Startups
Nirogy Therapeutics' latest round of $16.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nirogy Therapeutics in Biotechnology and Natick
Companies Similar to Nirogy Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Nirogy Therapeutics Funding FAQs
What does Nirogy Therapeutics do?
Nirogy Therapeutics is a biotechnology company developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.
How much funding has Nirogy Therapeutics raised?
Nirogy Therapeutics has raised $16.5M across 1 round on record. The most recent is a Series A of $16.5M announced in Jan 2021.
When did Nirogy Therapeutics last raise funding?
Nirogy Therapeutics' most recent funding round on record is a Series A of $16.5M, announced in Jan 2021.
Who is the CEO of Nirogy Therapeutics?
Vincent Sandanayaka is listed as CEO at Nirogy Therapeutics.
Where is Nirogy Therapeutics headquartered?
Nirogy Therapeutics is based in Natick, Massachusetts, United States.
How many employees does Nirogy Therapeutics have?
Nirogy Therapeutics is in the 1-10 employee band.
How does Nirogy Therapeutics' funding compare to other Biotechnology startups?
Nirogy Therapeutics' latest round of $16.5M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Nirogy Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nirogy Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.